The most notable companies in this group are Intra-Cellular Therapies (NASDAQ:ITCI).
The investment seeks long-term growth of capital.
The fund adviser seeks to provide higher risk-adjusted returns with lower volatility compared to domestic equity markets. The adviser will establish long and short positions in a portfolio of equity securities of companies of all market capitalizations. Under normal market conditions, the advisor expects to invest the fund’s assets primarily (greater than 65%) in companies domiciled in the U.S. or listed on a U.S. exchange. The fund is non-diversified.
The average market capitalization across the Wasatch Long/Short Alpha Institutional MF is 13.89B. The market cap for tickers in the group ranges from 2.88B to 59.6B. ROP holds the highest valuation in this group at 59.6B. The lowest valued company is ICFI at 2.88B.
The average weekly volume growth across all stocks in the Wasatch Long/Short Alpha Institutional MF was 7%. For the same stocks of the MF, the average monthly volume growth was 18% and the average quarterly volume growth was -5%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 74
P/E Growth Rating: 52
Price Growth Rating: 43
SMR Rating: 61
Profit Risk Rating: 30
Seasonality Score: -52 (-100 ... +100)